PCI Pharma Services ("PCI" or the "Company"), a world-leading global contract development and manufacturing organization ...

The CDMO, which has been owned by different private investors over the last decade, will use the funds to broaden its ...

A Philadelphia-based pharmaceutical services company has just received a massive investment from two major private equity firms, reportedly catapulting its valuation to $10 billion.

PCI Pharma Services has received a strategic investment co-led by Bain Capital and existing lead investor Kohlberg, and ...

More recently, PCI acquired a 100% stake in Ajinomoto’s fill-finish contracting arm Ajinomoto Althea. The deal, for which ...

PCI asks State Councils to submit consolidated data of pharmacists for HPR: Our Bureau, New Delhi Saturday, July 19, 2025, 08 ...

Mubadala Investment Company, the Abu Dhabi-based sovereign wealth fund managing a global portfolio, is making a significant reinvestment in PCI Pharma Services (PCI).

The firms lead an investment valuing PCI Pharma at $10 billion, see the company benefiting from broader trends.

Bain Capital and Kohlberg have completed a strategic investment in PCI Pharma Services, according to a news release.

Part of $1 Billion Investment Strategy, PCI Pharma Services Completes Acquisition of Ajinomoto Althea, Enhancing US Drug Product Manufacturing for Aseptic Filling of Prefilled Syringes ...

Not letting its expansion efforts idle, contract manufacturer PCI Pharma Services is picking up a 100% stake in Ajinomoto's San Diego-based fill-finish CDMO Ajinomoto Althea. The deal, for which ...

Mubadala’s investment is part of a strategic transaction co-led by Bain Capital and existing lead investor Kohlberg ...